ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2775

Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort

Marion Pons 1, Nathalie Costedoat-Chalumeau 2, Karine Briot 3, Philippe Goupille 4, Christian Roux 5, Maxime Dougados 6 and Anna Moltó5, 1Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, 2Cochin University Hospital, Paris, France, 3Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 6Cochin Hospital, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, pregnancy and epidemiologic methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Only scarce data is available on regarding pregnancy rates and pregnancy outcomes in early axial spondyloarthritis (axSpA). The objectives of this study were to estimate the probability of achieving a clinical pregnancy and presenting an unfavorable pregnancy outcome, and determined their associated factors, in this population.

Methods: Observational prospective French cohort (DESIR) with 6y of follow-up, including 381 of TNF-naïve women with early axSpA. Study visits were scheduled every 6 months in the first two years and then yearly up to 6 years. Data on pregnancy were collected retrospectively (before cohort inclusion) and prospectively (since inclusion) up to 6y of follow-up. Baseline characteristics of nulligravidae and uni/multigravidae patients were compared. The probability of achieving at least one pregnancy over time was estimated (Kaplan Meier). Associated factors were estimated by Frailty Shared Models and mixed models taking into account the correlation between several pregnancies from the same women. The probability to present an unfavorable pregnancy outcome over time (i.e a miscarriage or pre-term delivery or an elective termination of pregnancy) was estimated only during the prospective period (Kaplan Meier). Associated factors to an unfavorable pregnancy outcome were estimated by multivariable Frailty shared Models and mixted models.

Results: Of the 381 women included in the analysis, 289 (75.9%) and 92 (24.1%) women were respectively multigravidae and nulligravidae at the end of the 6y follow-up. Multigravidae women were significantly older (36.7±8.2 vs 27.8 ± 7.2, p< 0.01), less educated (56.9% vs 72.5% university studies, p=0.01), and had higher BASDAI (4.9±1.9 vs 4.4±2.0, p=0.04), and higher BASFI (3.5±2.4 vs 2.8±2.2, p=0.008) scores at baseline. The probability to have at least one pregnancy throughout life was 61.8% [55.1-67.5]. The mean age of the first pregnancy was 27.3 years old.  One hundred and twenty-four pregnancies occurred during follow-up. Lack of TNFi use in the 6 months preceding the pregnancy outcome (HR=2.0 [95%CI 1.1-3.3], p=0.01) and a CRP≥ 6mg/L (HR=1.7 [95%CI 1.2-2.5], p=0.01) were found to be associated with pregnancy over follow-up.
Among the 80 pregnancies occurring after inclusion with data available on the outcome, 60 (75%) presented a full-term delivery while 12 (15%) presented an unfavorable pregnancy outcome (6 (7.5%) and 6(7.5%) had a miscarriage or a pre-term delivery, respectively), 2(2.5%) had an elective abortion, and 6(7.5%) were pregnancies still ongoing at the end of follow-up. The probability to present an unfavorable outcome was 16.7% [0.1-0.2]. Only NSAID use (HR=2.5 [95%CI 1.1-5.0], p=0.02) within 6 months of delivery were associated with an unfavorable outcome.

Conclusion: More than 70% patients had at least one pregnancy. A favorable pregnancy outcome (i.e.full-term delivery) was observed in 75% of patients, which is comparable to the general population data. Patients who achieved a pregnancy were more likely to have stopped their TNFi 6 months prior to the pregnancy outcome, and increased their CRP at the previous visit. NSAID use within 6 months of delivery was independently associated with an unfavorable pregnancy outcome.


Disclosure: M. Pons, None; N. Costedoat-Chalumeau, None; K. Briot, None; P. Goupille, AbbVie, 5, Amgen, 5, Biogaran, 5, BMS, 5, Celgene, 5, Eli Lilly, 5, Hospira, 5, Janssen-Cilag, 5, MSD, 5, Pfizer, 5, Sanofi-Genzyme, 5, UCB, 5; C. Roux, None; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; A. Moltó, None.

To cite this abstract in AMA style:

Pons M, Costedoat-Chalumeau N, Briot K, Goupille P, Roux C, Dougados M, Moltó A. Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pregnancy-rates-and-outcomes-in-early-axial-spondyloarthritis-analysis-of-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-rates-and-outcomes-in-early-axial-spondyloarthritis-analysis-of-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology